A Korean anticancer drug development company Wellmarker Bio(WMBIO) has recently discovered a novel target protein that could overcome the resistance to Cetuximab which is one of the most commonly used targeted therapy for colon cancer patients worldwide. This new anticancer therapy is known to be WMBIO’s lead asset under the name of WM-S1 and it is expected to enter Hit to Lead stage.